MARKET

SILO

SILO

Silo Pharma Inc
NASDAQ
1.750
0.000
0.00%
After Hours: 1.730 -0.02 -1.14% 17:05 09/25 EDT
OPEN
1.810
PREV CLOSE
1.750
HIGH
1.810
LOW
1.720
VOLUME
20.09K
TURNOVER
--
52 WEEK HIGH
15.15
52 WEEK LOW
1.630
MARKET CAP
3.07M
P/E (TTM)
-0.3281
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at SILO last week (0914-0918)?
Weekly Report · 5d ago
Biotech Stocks In Focus - IMCC +245%, XRTX +12%, SILO, BFRI
NASDAQ · 09/18 19:27
Silo Pharma receives U.S. patent allowance for SPC-15 PTSD treatment
TipRanks · 09/18 13:10
Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
Benzinga · 09/18 12:52
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Barchart · 09/18 07:50
Weekly Report: what happened at SILO last week (0907-0911)?
Weekly Report · 09/14 09:39
Silo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation Forum
NASDAQ · 09/09 15:28
More
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Webull offers Silo Pharma Inc stock information, including NASDAQ: SILO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SILO stock methods without spending real money on the virtual paper trading platform.